Ten stocks soared higher on Tuesday, bucking a broader market decline, thanks to company-specific catalysts that sparked buying appetite.
In contrast, Wall Street’s main indices ended in a lackluster note, with the tech-heavy Nasdaq the only gainer, albeit inching up by only 0.03 percent. The Dow Jones and the S&P 500, on the other hand, 0.37 percent and 0.07 percent, respectively.
In this article, we name the 10 top performers on Tuesday and detail the reasons behind their gains.
To come up with the list, we considered only the stocks with at least $2 billion in market capitalization and over 5 million shares in trading volume.
10. Albermarle Corporation (NYSE:ALB)
Albermarle Corp. rebounded by 7.21 percent on Tuesday to close at $70.22 apiece as investor sentiment was bolstered by an investment firm’s bullish rating for its stock.
In a market note, Jefferies reaffirmed its “buy” recommendation for Albermarle Corporation (NYSE:ALB), but lowered its price target for its stock to $84 from $85 previously. Still, the new figure marked a 19.6-percent upside from its latest closing price.
Meanwhile, Albermarle Corporation (NYSE:ALB) earned a more conservative “Hold” recommendation from Zacks Research, on expectations that it would post sales of $1.21 billion for the current quarter or a -15 percent change year-on-year.
Meanwhile, it sees the company recording $4.86 billion and $5.35 billion in sales for the current and next fiscal years indicating changes of -9.5 percent and +9.9 percent, respectively.
Albermarle Corporation (NYSE:ALB) is a US-based specialty chemicals manufacturing company that serves various industries, including agriculture, automotive, aviation, building and construction, among others.
9. Intel Corporation (NASDAQ:INTC)
Intel Corp. rallied by 7.23 percent on Tuesday to close at $23.59 apiece as investor sentiment was buoyed by its ongoing corporate restructuring plan to claw back to profitability.
Part of the move will see 529 jobs laid off across four major campuses in Oregon beginning July 15, the company said. The layoffs will affect employees at the Aloha, Hawthorne Farms, Ronler Acres, and Intel Jones campuses in Hillsboro.
“We are taking steps to become a leaner, faster, and more efficient company. Removing organizational complexity and empowering our engineers will enable us to serve the needs of our customers better and strengthen our execution,” Intel Corporation (NASDAQ:INTC) said.
“We are making these decisions based on careful consideration of what’s needed to position our business for the future, and we will treat people with care and respect as we complete this important work,” it added.
The recent job cuts form part of the company’s plan to reduce its workforce by 15 to 20 percent, citing affordability challenges and its current financial position.
8. Transocean Ltd. (NYSE:RIG)
Transocean ended two straight days of losses on Tuesday, jumping 8.12 percent to close at $2.93 apiece following the Department of Energy’s warning that blackouts could spike by 100 times by 2030 if supplies fail to cover peak demand.
In a report, the DOE cited the huge difference between electricity demand and supply, especially with the growing energy needs of the power-hungry artificial intelligence sector.
The department said that it expects 209 gigawatts of new electricity to be generated by 2030 and replace 104 GW of plant retirements. However, only 22 GW of the new energy will come from power sources that provide stable and continuous power supply, raising outage risk in several regions.
While the DOE’s findings highlighted the risks for the overall sector, its increasing focus also underscored the need for energy security, which could strengthen support for traditional energy sources like oil and gas, and in turn, benefit oil and gas drilling operators such as Transocean Ltd. (NYSE:RIG).
With the global rising demand and utilities scrambling to secure more energy sources, Transocean Ltd. (NYSE:RIG) could help close the supply gap through ramped-up drilling operations.
7. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Recursion Pharmaceuticals bounced back by 8.72 percent on Tuesday to close at $5.36 apiece following news that it acquired a $25-million interest in REV102—an ENPP1 inhibitor in preclinical development for the treatment of hypophosphatasia.
In a statement on Tuesday, Rallybio said it entered into a definitive agreement with Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) for the sale of its interest, under which it will be eligible to receive $7.5 million in upfront equity, a contingent equity payment of $12.5 million upon the initiation of additional preclinical studies, and a $5 million milestone payment in connection with the initiation of dosing in a Phase 1 clinical study.
It will also be eligible to receive low single-digit royalties on all future net sales by Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) and likewise earn payments in the event of the latter’s sale of the REV102 program.
“By combining Rallybio’s expertise in HPP preclinical and translational research with Recursion’s integrated AI/experimental platform, we transformed this concept into the first potential oral disease-modifying treatment for HPP,” said Rallybio CEO Stephen Uden.
6. Moderna, Inc. (NASDAQ:MRNA)
Moderna Inc. jumped by 8.83 percent on Tuesday to close at $32.54 apiece as investor sentiment was boosted by a lawsuit filed against Health Secretary Robert F. Kennedy Jr. over policies on COVID-19 vaccines.
On Monday, six medical organizations sued Kennedy and the Department of Health and Human Services over the agency’s decision to limit vaccine access. The plaintiffs sought to restore the COVID-19 vaccine to the list of recommended immunizations for healthy children and pregnant women.
The plaintiffs include the American Public Health Association, the American Academy of Pediatrics, the Infectious Diseases Society of America, the American College of Physicians, the Society for Maternal-Fetal Medicine and the Massachusetts Public Health Alliance.
“The secretary’s intentions are clear. He (Kennedy) aims to destroy vaccines,” said Richard Hughes IV, a lawyer who teaches vaccine law at George Washington University, who is leading the effort.
The lawsuit was viewed as a tailwind for Moderna, Inc. (NASDAQ:MRNA), one of the few pharmaceutical companies that successfully developed its own COVID-19 vaccine during the pandemic.
5. Lucid Group, Inc. (NASDAQ:LCID)
Lucid Group saw its share prices rise by 9 percent on Tuesday to close at $2.3 apiece as investors cheered its achievement of a Guinness World Record title for recording the longest journey using its electric vehicle on a single charge.
In a statement on Tuesday, Lucid Group, Inc. (NASDAQ:LCID) said that its Lucid Air Grand Touring covered a range of 1,205 kilometers without charging between St. Moritz, Switzerland, and Munich, Germany, across alpines, highways, and secondary roads.
Lucid Group, Inc. (NASDAQ:LCID) exceeded its previous record for the longest journey of 1,045 kilometers in June 2025 by 160 kilometers.
“This range record represents a significant milestone—it’s yet another clear demonstration of the technological edge that defines Lucid,” said Lucid Group, Inc. (NASDAQ:LCID) SVP and Chief Engineer Erich Bach.
The new record can potentially boost Lucid Group, Inc.’s (NASDAQ:LCID) brand reputation and consumer confidence, and in turn, drive increased vehicle reservations, stronger demand, and higher revenues.
4. Viking Therapeutics, Inc. (NASDAQ:VKTX)
Viking Therapeutics jumped by 9.74 percent on Tuesday to close at $30.19 apiece as investors repositioned portfolios ahead of the expected release of the results of its own weight loss drug clinical trial.
In a statement, Viking Therapeutics, Inc. (NASDAQ:VKTX) said it expects to report the phase 2 trial data for its weight loss drug candidate VK2735 after 13 weeks of trial. The trial enrolled late in March approximately 280 obese adults with at least one weight-related co-morbid condition.
The primary endpoint of the study is to find the percentage change in body weight from baseline after 13 weeks of treatment. Secondary and exploratory endpoints will evaluate a range of additional safety and efficacy measures.
Viking Therapeutics, Inc. (NASDAQ:VKTX) previously reported positive results from a 28-day Phase 1 multiple ascending dose (MAD) clinical trial of the tablet formulation of VK2735 in healthy volunteers.
According to the company, receiving VK2735 demonstrated dose-dependent reductions in mean body weight from baseline, ranging up to 8.2 percent.
3. The Chemours Company (NYSE:CC)
The Chemours Company (NYSE:CC) saw its share prices increase by 9.74 percent on Tuesday to end at $13.63 apiece following the US Environmental Protection Agency’s (EPA) decision to withdraw a plan to ban chrysotile asbestos.
Chrysotile asbestos, also known as white asbestos, is commonly used in buildings and industrial applications.
It is currently banned in over 50 countries for its connection to lung cancer and mesothelioma. However, it is imported for use in the US for roofing materials, textiles, and cement, and is also used in gaskets, clutches, brake pads, and other automotive parts, as well as in chlorine manufacturing.
The EPA adopted a ban in 2024 on the use, manufacture, and import of chrysotile asbestos.
The Chemours Company (NYSE:CC), for its part, uses the mineral in operations involving titanium dioxide.
2. SoundHound AI, Inc. (NASDAQ:SOUN)
SoundHound AI rallied for a second day on Tuesday, jumping 11.69 percent to finish at $12.71 apiece as investors took path from the booming capabilities of Agentic AI.
Agentic AI refers to artificial intelligence systems designed to act autonomously, make decisions, and take actions to achieve goals with limited human intervention.
SoundHound AI, Inc. (NASDAQ:SOUN), which offers Agentic AI tools through voice automation, rose in line with its counterparts namely Salesforce, Bigbear.ai, RingCentral, Five9, and C3.ai, among others.
According to Zacks Research, SoundHound AI, Inc. (NASDAQ:SOUN) is set to benefit from the rising customer demand for quick service and labor shortages which are driving restaurants to adopt voice automation.
“SoundHound AI anticipates 2025 revenues of $157 million to $177 million, up from last year’s $84.7 million,” it said. “SoundHound AI’s 2024 booking backlog of $1.2 billion suggests strong long-term revenue growth, alongside a total addressable market (TAM) of $140 billion, indicating the potential for further expansion.”
1. QuantumScape Corporation (NYSE:QS)
QuantumScape jumped by 16.69 percent on Tuesday to end at $8.18 apiece as investors repositioned portfolios ahead of the expected release of its second-quarter earnings later this month.
Based on its historical earnings reporting dates, QuantumScape Corporation (NYSE:QS) will report its financial and operating results in the third or fourth week of July.
Investors will be closely watching out for the company’s earnings and production outlook for the short-term period, given the recent achievement of a milestone through the integration of the advanced Cobra separator process into baseline cell production.
According to QuantumScape Corporation (NYSE:QS), Cobra forms the foundation of its high-throughput, continuous-flow separator production platform. It was designed to enable faster, more energy-efficient production with a smaller equipment footprint compared to earlier processes, and represents a step-change improvement in ceramic separator manufacturing.
“Compared to the prior-generation Raptor process, Cobra offers a ~25x improvement in heat treatment speed and occupies a fraction of the physical space per film start—key advantages in the design of a scalable gigafactory production line,” QuantumScape Corporation (NYSE:QS) said.
While we acknowledge the potential of QS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than QS and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.
